The State Drug Administration of the Communist Party of China (SFDA) on February 25 granted conditional marketing approval for two vaccines against the Chinese Communist Party virus (neo-coronavirus), one of which is an adenovirus vector vaccine from Kangxinuo Bio. Chen Wei, a major general in the Chinese military who led the research and development, claimed that the vaccine would have a capacity of 500 million doses this year.
The Chinese Communist Party is engaged in “vaccine diplomacy”. Chen Wei’s team announced the development of the vaccine as early as February 26 last year, and then suddenly went on the market a year later, becoming China’s third vaccine to be listed with conditions, raising concerns.
Conditional listing approved quickly, safety questioned
China has already launched four Chinese communist virus vaccines, including the recombinant virus vaccine “Kvisa” (type 5 adenovirus vector), which was developed by the team of Kangxinuo Biological Company and Chen Wei, a Chinese communist military academician.
The conditional marketing application for the vaccine was only accepted on February 21 and approved on February 25.
On February 26, Chen Wei said on CCTV that the vaccine they developed is genetically engineered, and that the most important feature is that it can be produced quickly, with a capacity of 500 million doses this year, and the effect can last for six months.
In a video speech last September, Chen Wei revealed that the vaccine had begun preparations for mass production on February 26, and that “the target of 300 million annual production is achievable.
Current affairs commentator Tang Jingyuan said, “The Chinese Communist Party is now desperately trying to seize the vaccine market, mainly by using the vaccine as a political weapon to break through diplomatic isolation and to shirk responsibility for the plague pandemic. But the adenovirus vector vaccine is not as good as Chen Wei boasts. There are general problems with this vaccine in terms of safety and Epidemic prevention effectiveness.”
“This vaccine, because it uses Ad5 adenovirus as a vector, but this adenovirus has a very high infection rate in the population, averaging more than 40 percent in Asia and the Americas, and up to 80 percent in Africa, so it is likely that a significant portion of the adenovirus vector could be neutralized by antibodies already in the body, resulting in a loss of immune protection.” He said.
In terms of safety, Tang Jingyuan analyzed, “CCP is completely opaque in terms of development and testing, so there is no way to assess the true state of its safety. But the British Oxford AstraZeneca vaccine, which follows the same technical path as Kvisa, was previously called off at one point because of serious adverse reactions.”
As early as a year ago (March 3, 2020), it was rumored online that Chen Wei’s team had developed the first batch of the CCP virus vaccine, and a photo of the vaccine vial was posted. The vial packaging showed that the vaccine was produced on February 26, 2020, was valid until February 25, 2022, and was produced by the Military Hospital of the Academy of Military Sciences and Kangxino Biological JSC.
The rapid development of vaccines by the Chinese military has raised concerns
The CCP identified the human-to-human transmission of the CCP virus on January 19, 2020, and on January 26, Chen Wei went to sit in Wuhan, where she is China’s chief biochemical weapons defense expert. A month later, on February 26, Chen Wei’s team announced the development of a recombinant virus vaccine, which was approved for clinical trials on March 16.
The speed with which the vaccine was launched with the involvement of the Chinese Communist Party’s military in its development has raised concerns.
WHO has used the influenza virus as an example in the past, stating that it takes about five to six months to identify and isolate a new strain of the virus, and then begin developing a vaccine on that basis. A study by Dr. Yan Limeng, formerly with the University of Hong Kong, and a top team from the United States, said that the CCP virus could be conveniently synthesized in the laboratory in just six months, and that it is possible that the virus could start spreading in August 2019.
Meanwhile, the internet has inventoried some coincidences in the timing.
(1) On September 18, 2019, the Chinese Communist Party (CCP) held a drill at Wuhan Tianhe Airport on “emergency response to the new coronavirus”; the new term “new coronavirus” was introduced for the first Time.
(2) The World Military Games are held in Wuhan from October 18-27, 2019.
(3) On November 17, 2019, the South China Morning Post exclusively reported that the first case of Wuhan pneumonia was confirmed.
4) Kangxino Bio was listed in Hong Kong in March 2019 and its share price has been hovering around 30 RMB for a long time. After the “New Coronavirus Emergency Treatment” exercise in Wuhan, shares of Conxino Biologicals started to move in October 2019 and started to rise in volume in mid-November, which was bought by investors and doubled by the end of December.
Current affairs commentator Chen Weiyu questions who was so predictable in buying this tranche of shares in mid-November 2019? It makes one wonder if the vaccine had been developed by then for such good news to drive the stock soaring. And Chen Wei could have launched the vaccine so early because they had the strain long ago.
Recent Comments